SRFNSE:SRF
Current view Q1 2027
Real engine is refrigerant gases, where global quota rules let it run plants flat out while prices stay firm, and management is unusually candid. The latest numbers are flattered by a war-driven windfall management says will fade, and the big new plant and the Chemours contract only start paying from FY28.
Latest exchange filings last 5 · 5 after Q1 2027
- 10 Sep ’26Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011 10 Sep ↗
- 29 Jul ’26Transcript of the Earnings Call held on 23rd July 2026 ↗
- 27 Jul ’26Income tax demand for AY 2022-23 reduced from Rs 327.44 crore to Rs 9.46 crore. ↗
- 23 Jul ’26SRF offers documents submission facility for lower or nil TDS on dividend by 30 July 2026. ↗
- 23 Jul ’26Announcement under Regulation 30 (LODR)-Earnings Call Transcript 23 Jul ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q1 2027
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q1 2027
| Metric | This year vs lastYoY · vs Q1 2026 | vs the quarter beforeQoQ, sequential · vs Q4 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +31.8% | +9.1% | +2.0% | +13.4% |
| Operating profit | ▲ +49.0% | +20.6% | −1.6% | +9.3% |
| EPS | ▲ +75.6% | +30.4% | −5.3% | +8.9% |
| PAT | ▲ +75.7% | +30.4% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +31.8%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Poor21/100
Earnings are shrinking, not growing. Profit per share fell 5% a year over the window measured. Nothing compounds from here until that turns, whatever the price does.
No forward view — earnings are not compounding, so there is nothing to project.
Multiple moved without the earnings — the return sits in sentiment.
How this is calculated
Band capped: earnings are not growing over the measured window.
Growth rate used: -5.3% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 60%.
How it compares with its rivals Speciality Chemicals · 6 of 44 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| SRF | ₹2,556 | 33.8× | ₹75,768 Cr | 14.6% | +75.5% | +31.8% |
| Tata Chemicals | ₹699 | — | ₹17,809 Cr | 3.4% | −106.8% | +14.4% |
| Deepak Fertilis. | ₹1,331 | 17.1× | ₹16,802 Cr | 11.4% | +101.5% | +22.5% |
| G N F C | ₹589 | 8.3× | ₹8,659 Cr | 12.0% | +275.9% | +39.8% |
| Tanfac Inds. | ₹3,501 | 112.0× | ₹7,574 Cr | 23.9% | −12.9% | +6.3% |
| Gujarat Alkalies | ₹632 | 70.0× | ₹4,645 Cr | 1.4% | +499.0% | +12.7% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | yes — a little wider than 3 years earlier | operating margin 21% → 25% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it arrived as cash | 90% last year, 97% over three · free cash flow ₹747 cr, positive in 4 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹5,083 cr — 0.36× its own equity (was 0.37×) |
| Is it being collected? | collection is steady | 59 days to collect, up 5 in a year · cash cycle 69 days |
| Who has been buying? | the promoters have held steady | promoters 50.3%, 50.5% → 50.3% over 2.8 years · FIIs 15.4% (−2.8) · DIIs 22.4% (+3.6) · shareholders 2,71,170 → 1,77,423 |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 14.6% · ROE 14.3% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
Against it
- Stock is trading at 5.40 times its book value
- Company has a low return on equity of 12.4% over last 3 years.
- Company might be capitalizing the interest cost
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.